{
    "root": "3540f59e-f085-8760-e063-6394a90aae82",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Aripiprazole",
    "value": "20250516",
    "ingredients": [
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13404"
        },
        {
            "name": "FRUCTOSE",
            "code": "6YSS42VSEV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28757"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "MALIC ACID",
            "code": "817L1N4CKP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6650"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "ORANGE",
            "code": "5EVU04N5QU",
            "drugbank_id": "https://go.drugbank.com/drugs/DB10549"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32063"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "ARIPIPRAZOLE",
            "code": "82VFR53I78",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31236"
        }
    ],
    "indications": {
        "text": "aripiprazole oral solution indicated treatment : schizophrenia [ ( 14.1 ) ] acute treatment manic mixed episodes associated bipolar disorder [ ( 14.2 ) ] adjunctive treatment major depressive disorder [ ( 14.3 ) ] irritability associated autistic disorder [ ( 14.4 ) ] treatment tourette \u2019 disorder [ ( 14.5 ) ]",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "autistic disorder (DOID:12849)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12849"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "initial dose recommended dose maximum dose schizophrenia - adults ( 2.1 ) 10 15 mg/day 10 15 mg/day 30 mg/day schizophrenia - adolescents ( 2.1 ) 2 mg/day 10 mg/day 30 mg/day bipolar mania - adults : monotherapy ( 2.2 ) 15 mg/day 15 mg/day 30 mg/day bipolar mania - adults : adjunct lithium valproate ( 2.2 ) 10 15 mg/day 15 mg/day 30 mg/day bipolar mania - pediatric patients : monotherapy adjunct lithium valproate ( 2.2 ) 2 mg/day 10 mg/day 30 mg/day major depressive disorder - adults adjunct antidepressants ( 2.3 ) 2 5 mg/day 5 10 mg/day 15 mg/day irritability associated autistic disorder - pediatric patients ( 2.4 ) 2 mg/day 5 10 mg/day 15 mg/day tourette \u2019 disorder - ( 2.5 ) patients < 50 kg 2 mg/day 5 mg/day 10 mg/day patients > 50 kg 2 mg/day 10 mg/day 20 mg/day oral formulations : administer daily without regard meals ( 2 ) known cyp2d6 poor metabolizers : half usual dose ( 2.7 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "autistic disorder (DOID:12849)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12849"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "aripiprazole oral solution contraindicated patients history hypersensitivity reaction aripiprazole . ranged pruritus/urticaria anaphylaxis [ ( 6.2 ) ] .",
    "indications_original": "Aripiprazole oral solution is indicated for the treatment of:\n                  \n                     Schizophrenia\n  \n   [see\n   \n    Clinical Studies (14.1)]\n  \n   \n                     \n                     Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder\n  \n   [see\n   \n    Clinical Studies (14.2)]\n  \n   \n                     \n                     Adjunctive Treatment of Major Depressive Disorder\n  \n   [see\n   \n    Clinical Studies (14.3)]\n  \n   \n                     \n                     Irritability Associated with Autistic Disorder\n  \n   [see\n   \n    Clinical Studies (14.4)]\n  \n   \n                     \n                     Treatment of Tourette\u2019s Disorder\n  \n   [see\n   \n    Clinical Studies (14.5)]",
    "contraindications_original": "Initial Dose Recommended Dose Maximum Dose Schizophrenia - adults ( 2.1 ) 10 to 15 mg/day 10 to 15 mg/day 30 mg/day Schizophrenia - adolescents ( 2.1 ) 2 mg/day 10 mg/day 30 mg/day Bipolar mania - adults: monotherapy ( 2.2 ) 15 mg/day 15 mg/day 30 mg/day Bipolar mania - adults: adjunct to lithium or valproate ( 2.2 ) 10 to 15 mg/day 15 mg/day 30 mg/day Bipolar mania - pediatric patients: monotherapy or as an adjunct to lithium or valproate ( 2.2 ) 2 mg/day 10 mg/day 30 mg/day Major Depressive Disorder - Adults adjunct to antidepressants ( 2.3 ) 2 to 5 mg/day 5 to 10 mg/day 15 mg/day Irritability associated with autistic disorder - pediatric patients ( 2.4 ) 2 mg/day 5 to 10 mg/day 15 mg/day Tourette\u2019s disorder - ( 2.5 ) Patients < 50 kg 2 mg/day 5 mg/day 10 mg/day Patients > 50 kg 2 mg/day 10 mg/day 20 mg/day Oral formulations: Administer once daily without regard to meals ( 2 ) Known CYP2D6 poor metabolizers: Half of the usual dose ( 2.7 )",
    "adverseReactions_original": "Aripiprazole oral solution is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. Reactions have ranged from pruritus/urticaria to anaphylaxis\n \n  [see\n  \n   Adverse Reactions (6.2)]\n \n  .",
    "drug": [
        {
            "name": "Aripiprazole",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31236"
        }
    ]
}